CA2923406A1 - Methods and compositions for viral vectored vaccines - Google Patents
Methods and compositions for viral vectored vaccines Download PDFInfo
- Publication number
- CA2923406A1 CA2923406A1 CA2923406A CA2923406A CA2923406A1 CA 2923406 A1 CA2923406 A1 CA 2923406A1 CA 2923406 A CA2923406 A CA 2923406A CA 2923406 A CA2923406 A CA 2923406A CA 2923406 A1 CA2923406 A1 CA 2923406A1
- Authority
- CA
- Canada
- Prior art keywords
- vector
- vaccine
- animal
- poly
- iclc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title abstract description 22
- 230000003612 virological effect Effects 0.000 title description 6
- 229940027570 adenoviral vector vaccine Drugs 0.000 claims abstract description 90
- 239000013598 vector Substances 0.000 claims abstract description 86
- 108091007433 antigens Proteins 0.000 claims abstract description 44
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 102000036639 antigens Human genes 0.000 claims abstract description 42
- 230000028993 immune response Effects 0.000 claims abstract description 36
- 239000000556 agonist Substances 0.000 claims abstract description 30
- 230000005847 immunogenicity Effects 0.000 claims abstract description 22
- 230000001681 protective effect Effects 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 6
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims abstract 10
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims abstract 10
- 108700002563 poly ICLC Proteins 0.000 claims description 70
- 241001465754 Metazoa Species 0.000 claims description 69
- 239000012648 POLY-ICLC Substances 0.000 claims description 68
- 229940115270 poly iclc Drugs 0.000 claims description 68
- 239000012646 vaccine adjuvant Substances 0.000 claims description 35
- 241000701161 unidentified adenovirus Species 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 206010022000 influenza Diseases 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 102000005348 Neuraminidase Human genes 0.000 claims description 2
- 108010006232 Neuraminidase Proteins 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 101710194807 Protective antigen Proteins 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 229940118376 tetanus toxin Drugs 0.000 claims description 2
- 241000272525 Anas platyrhynchos Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 38
- 230000001976 improved effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 39
- 238000002255 vaccination Methods 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 20
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 19
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 17
- 239000002253 acid Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000004580 weight loss Effects 0.000 description 13
- 244000052769 pathogen Species 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 229940124931 vaccine adjuvant Drugs 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 9
- 108020000411 Toll-like receptor Proteins 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 8
- 229940047124 interferons Drugs 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 241001135569 Human adenovirus 5 Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000598171 Human adenovirus sp. Species 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000010740 swine influenza Diseases 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 241000430519 Human rhinovirus sp. Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229940023835 Ad-based vaccine Drugs 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100348738 Mus musculus Noc3l gene Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002235 anthrax antigen Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874505P | 2013-09-06 | 2013-09-06 | |
| US61/874,505 | 2013-09-06 | ||
| PCT/US2014/054234 WO2015035128A1 (en) | 2013-09-06 | 2014-09-05 | Methods and compositions for viral vectored vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2923406A1 true CA2923406A1 (en) | 2015-03-12 |
Family
ID=52625855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923406A Abandoned CA2923406A1 (en) | 2013-09-06 | 2014-09-05 | Methods and compositions for viral vectored vaccines |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150071964A1 (enExample) |
| EP (1) | EP3041503A4 (enExample) |
| JP (1) | JP2016529316A (enExample) |
| KR (1) | KR20160049010A (enExample) |
| AU (1) | AU2014315124A1 (enExample) |
| CA (1) | CA2923406A1 (enExample) |
| MX (1) | MX2016002823A (enExample) |
| WO (1) | WO2015035128A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| CN114222817A (zh) * | 2019-04-06 | 2022-03-22 | 艾尔特免疫公司 | 广泛且持久的流感疫苗 |
| US20230210979A1 (en) * | 2020-04-20 | 2023-07-06 | Greffex, Inc. | Engineering broadly reactive coronavirus vaccines and related designs and uses |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2712673C2 (de) * | 1977-03-23 | 1983-12-15 | Krauss U. Reichert Gmbh + Co Kg Spezialmaschinenfabrik, 7012 Fellbach | Stoßmessermaschine |
| US20030134815A1 (en) * | 1991-08-20 | 2003-07-17 | The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO2005102278A1 (en) * | 2002-07-03 | 2005-11-03 | Oncovir, Inc. | Method for preparation of poly-iclc and uses thereof |
| US8592391B2 (en) * | 2003-07-01 | 2013-11-26 | Andres Salazar | Method for therapeutic, clinical and veterinary use poly-ICLC |
| EP1648388A4 (en) * | 2003-07-11 | 2009-04-01 | Vaxin Inc | NEW OBJECTIVES AND COMPOSITIONS FOR USE IN DECONTAMINATION, IMMUNOPROPHYLAXIS AND THERAPY AFTER EXPOSURE TO MILZBRAND |
| US7834064B2 (en) * | 2005-01-03 | 2010-11-16 | Andres Mario Salazar | Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs |
| EP1899470A4 (en) * | 2005-05-23 | 2009-07-29 | Vaxin Inc | SYSTEM FOR THE FAST MANUFACTURE OF REPLICATED COMPETENCE OF ADENOVIRUS-FREE RECOMBINANT ADENOVIRUS VECTORS WITH HIGH TITER |
| ES2620789T3 (es) * | 2005-08-15 | 2017-06-29 | Altimmune Inc. | Inmunización de aves por administración de vacunas con vectores no replicantes |
| CN103122360A (zh) * | 2006-02-28 | 2013-05-29 | 瓦克萨特公司 | 嵌合腺病毒载体 |
| CN102056622B (zh) * | 2008-06-05 | 2016-04-06 | 免疫疫苗技术有限公司 | 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物 |
| KR20110081222A (ko) * | 2008-09-26 | 2011-07-13 | 어번 유니버시티 | 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화 |
| AU2010232180B2 (en) * | 2009-03-31 | 2016-09-22 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
| WO2010142017A1 (en) * | 2009-06-09 | 2010-12-16 | Defyrus, Inc . | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
| WO2012129295A1 (en) * | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
-
2014
- 2014-09-05 JP JP2016540407A patent/JP2016529316A/ja active Pending
- 2014-09-05 CA CA2923406A patent/CA2923406A1/en not_active Abandoned
- 2014-09-05 MX MX2016002823A patent/MX2016002823A/es unknown
- 2014-09-05 EP EP14841665.4A patent/EP3041503A4/en not_active Withdrawn
- 2014-09-05 US US14/478,040 patent/US20150071964A1/en not_active Abandoned
- 2014-09-05 AU AU2014315124A patent/AU2014315124A1/en not_active Abandoned
- 2014-09-05 KR KR1020167008956A patent/KR20160049010A/ko not_active Withdrawn
- 2014-09-05 WO PCT/US2014/054234 patent/WO2015035128A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3041503A1 (en) | 2016-07-13 |
| KR20160049010A (ko) | 2016-05-04 |
| JP2016529316A (ja) | 2016-09-23 |
| US20150071964A1 (en) | 2015-03-12 |
| EP3041503A4 (en) | 2017-06-07 |
| WO2015035128A1 (en) | 2015-03-12 |
| AU2014315124A1 (en) | 2016-04-07 |
| MX2016002823A (es) | 2016-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6943908B2 (ja) | 迅速かつ持続的な免疫学的治療法 | |
| US11141477B2 (en) | Rapid and prolonged immunologic-therapeutic | |
| US20150071964A1 (en) | Methods and compositions for viral vectored vaccines | |
| KR20110081222A (ko) | 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화 | |
| Garulli et al. | Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo | |
| US20240226273A1 (en) | Highly Attenuated Replication-Competent Recombinant Poxvirus As A Vaccine Platform And Methods Of Use | |
| Rosenthal et al. | Filling the immunological gap: recombinant viral vectors for mucosal vaccines | |
| EP4472665A2 (en) | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections | |
| Haroldo ToroA et al. | Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5 | |
| Nanda | IMMUNOLOGICAL EVALUATION OF MANNOSYLATED CHITOSAN NANOPARTICLES-BASED FMD VIRUS DNA VACCINE (pVAC-VP1-ompA) IN GUINEA PIGS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200908 |